The Effect of vitamins and/or antioxidants on lipid profile and homocysteine in type 2 diabetes

The Effect of vitamins and/or antioxidants on lipid profile and homocysteine in type 2 diabetes: A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201102125805N1

Enrollment

110

Registered

2011-04-10

Start date

2003-01-02

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Ggroup B: 10mg riboflavin, 10mg pyridoxine, 200µg cobalamin and 1000µg folic acid. Intervention 2: Group BE: same as group B and 100mg vitamin E. Intervention 3: Group BC: same as grou

Treatment - Drugs

Placebo

Ggroup B: 10mg riboflavin, 10mg pyridoxine, 200µg cobalamin and 1000µg folic acid

Group BE: same as group B and 100mg vitamin E

Group BC: same as group B and 200mg vitamin C

Group BCE: same as group BC and 100mg vitamin E

Group P: Placebo

Eligibility

Sex/Gender

All

Age

29 Years to 68 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients with fasting serum glucose over 126 mg/dl and having diabetes for at least 1 year with no abnormal hepatic or renal function, history of myocardial infarction or taking vitamin supplements. Exclusion Criteria: Unitention to continue the program and Patients who didn't take 10% of their capsules or report any side effects.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Homocysteine. Timepoint: Before treatment and after 2 months intervention. Method of measurement: An enzyme-linked immunoassay.	—

Secondary

Measure	Time frame
Triglyceride. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Enzymatically.;HDL. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Enzymatically.;LDL-c. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Enzymatically.;Apo A1. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Immunoturbidimetric method.;Total Cholesterol. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Enzymatically.;Apo B. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Immunoturbidimetric method.	—

Measure

Time frame

Triglyceride. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Enzymatically.;HDL. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Enzymatically.;LDL-c. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Enzymatically.;Apo A1. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Immunoturbidimetric method.;Total Cholesterol. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Enzymatically.;Apo B. Timepoint: Before treatment and after 2 months intervention. Method of measurement: Immunoturbidimetric method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvaneh Yavari

Tehran University Of Medical Sciences, School of Public Health, Department of nutrition and BioChemi

pyavari@sina.tums.ac.ir+98 21 8895 4924

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026